Highest-materiality recent filing
Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income
Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.
Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft
Net purchase price of $135M funded via $150M delayed draw term loan.
Artivion stockholders elect all nine director nominees and approve say-on-pay at 2026 annual meeting
All nine nominees elected; highest vote count for Anthony B. Semedo (39,241,704 for) and lowest for Jeffrey H. Burbank (34,250,202 for).
Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net
Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.
Artivion Q4 revenue $116M (+19%), GAAP net income $2.4M; full year $441M
GAAP revenue Q4 $116.0M vs $97.3M, net income $2.4M ($0.05 diluted EPS) vs net loss $16.5M in Q4 2024.
Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance
Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.
Artivion (AORT) to acquire two Austin office/manufacturing buildings for $20.5M cash
Purchase price $12.05M for existing On-X manufacturing buildings (75k sq ft) and $8.45M for adjacent 87k sq ft expansion.
Artivion extends credit facility maturities to 2031, adds $150M delayed draw term loan
Maturity of existing term loans and revolving credit facility extended to January 18, 2031.
Artivion appoints Lance Berry as COO, retains CFO role; CMO Stanton to retire March 2026
Lance Berry appointed COO effective Aug 11, 2025, while continuing as CFO and Treasurer.
Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance
Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.
Artivion exchanges $99.5M of convertible notes for 4.3M shares; nearly eliminates 2025 debt
Exchanged $99.54M principal of 4.250% convertibles due 2025 for 4,334,347 shares of common stock.
Artivion shareholders approve 3.57M share increase for equity incentive plan
All nine director nominees elected; say-on-pay and auditor ratification approved.
Artivion agrees to exchange ~$95M of 2025 convertible notes for common stock
Enters private exchange agreements with holders of 4.250% convertible notes due July 2025; ~$94.54M principal to be exchanged for shares.
Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance
Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.
Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M
Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.
On Dec 23, 2024, Artivion notified holders it is changing the default settlement method for its convertible notes to Physical Settlement.
Artivion reports cybersecurity incident discovered Nov 21; systems taken offline
Incident involved acquisition and encryption of files; external advisors engaged.
HDE covers ~40% of US acute DeBakey Type I dissections; PMA expected late 2025 for full $150M annual market.
Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M
Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.
Artivion Q2 revenue $98M (+10% YoY), narrows net loss, raises FY24 guidance
Revenue $98.0M (+10% GAAP and constant currency); net loss ($2.1M) vs ($3.4M) YoY.
Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net
Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.
Artivion amends bylaws, narrows stockholder advance notice requirements
Board approved amended bylaws effective May 15, 2024; updates advance notice rules for stockholder nominations and proposals.
Artivion stockholders approve officer exculpation charter amendment at 2024 annual meeting
Stockholders approved amendment to certificate of incorporation allowing officer exculpation under Delaware law; effective May 15, 2024.
Artivion Q1 revenue $97.4M (+17% YoY); nets $7.5M income vs loss; raises FY24 guidance
Revenue $97.4M, up 17% GAAP (16% constant currency) vs $83.2M in Q1 2023.
Artivion Q4 revenue $93.7M (+18% YoY); guides 2024 rev $382-396M
Q4 revenue $93.7M (+18% GAAP, +15% constant currency); full year $354.0M (+13%).
Artivion enters $350M credit facility with Ares Capital, refinances existing debt
Entered $350M credit facility: $190M initial term loan, $100M delayed draw term loan, $60M revolving credit facility.
Artivion appoints Lance A. Berry as CFO; Ashley Lee to retire after nearly 30 years
D. Ashley Lee, EVP & CFO, retires effective Dec 31, 2023; will serve as consultant for 1 year.
Artivion Q3 revenue $87.9M (+14% YoY); raises FY2023 revenue and EBITDA guidance
Revenue $87.9M, up 14% GAAP and 12% constant currency vs Q3 2022; net loss ($9.8M) or ($0.24)/share.
Artivion amends Bylaws to adopt universal proxy card rules and update governance provisions
Extends stockholder notice period for director nominations and business proposals.
Artivion Q2 revenue $89.3M (+11% YoY); raises FY revenue guidance to $342-350M
Net loss ($3.4M) or ($0.08)/share; non-GAAP net income $2.3M ($0.06)/share.
Artivion shareholders approve additional 3.04M shares for equity plan, re-elect directors
Stockholders approved 3,040,000 additional shares for the 2020 Equity and Cash Incentive Plan (30,752,663 for, 886,740 against).
Artivion Q1 revenue $83.2M (+8% GAAP, +10% constant currency); raises FY guidance
Net loss ($13.5M) or ($0.33)/share; non-GAAP net income $769k ($0.02)/share.
Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M
Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.
Artivion grants $6.6M in RSUs and options to executives; accelerates 2023 equity
Total grant date fair value of $6.6M under 2020 Equity and Cash Incentive Plan on Nov 8, 2022.
Artivion Q3 revenue $76.8M (+6% GAAP, +11% constant currency); net loss $0.34/share
Revenue $76.8M, up 6% GAAP and 11% constant currency vs Q3 2021.
Artivion appoints Elizabeth Hoff to Board of Directors effective Oct 1, 2022
Board expanded to nine directors; Hoff appointed to Compliance Committee.
Artivion stops PROACT Xa trial; apixaban fails non-inferiority vs warfarin for On-X aortic valves
DSMB recommended stopping PROACT Xa due to lack of evidence supporting non-inferiority of apixaban to warfarin.
Artivion board approves amended Code of Conduct in routine governance review
Board adopted amended and restated Code of Conduct on August 2, 2022, effective immediately.
Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M
Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.
All eight director nominees elected; votes for ranged from 26.6M (Burbank) to 29.3M (Borgstrom, Semedo).
Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share
Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).
Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M
Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.
CryoLife rebrands as Artivion; ticker changes to AORT from CRY effective Jan 24
Company renamed from CryoLife, Inc. to Artivion, Inc., effective January 18, 2022.
CryoLife reincorporates from Florida to Delaware effective Jan 1, 2022
Reincorporation from Florida to Delaware effective Jan 1, 2022; approved by stockholders on Nov 16, 2021.
CryoLife shareholders approve reincorporation from Florida to Delaware at special meeting
78% of outstanding shares represented; all three proposals passed with large majorities.
CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)
Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.
CryoLife appoints Anthony Semedo to board; director Ronald McCall passes away
Anthony Semedo appointed as director effective Oct 1, 2021; has 40+ years in med device, most recently at Medtronic.
CryoLife sells PerClot to Baxter for up to $60.8M; Q2 revenue up 42% to $76.1M
Total consideration up to $60.8M: $25M at closing ($19M to CryoLife), $25M upon FDA PMA approval, $10M sales milestones.
On December 4, 2023, D. Ashley Lee, the Executive Vice President, Chief Financial Officer and Treasurer of Artivion, Inc. (the “Company”), notified the Company of his decision to retire effective December 31, 2023 (the “Retirement Date”).
On December 4, 2023, the Company’s Board of Directors appointed Lance A. Berry as the Company’s Chief Financial Officer and Treasurer, effective as of that date.
increased the size of the Board to nine directors and appointed Elizabeth A. Hoff as a director and a member of the Compliance Committee of the Board, effective October 1, 2022.
on September 20, 2021, the Board of Directors (the “Board”) of CryoLife, Inc. (the “Company”) appointed Anthony B. Semedo as a director and a member of the Compliance Committee of the Board, effective on October 1, 2021.
the Company was informed on September 20, 2021 that Ronald D. McCall, Esq., a director of the Company since January 1984 and Presiding Director from December 2005 to March 2021, unexpectedly passed away.
Max materiality 0.85 · Median 0.68 · Most common event earnings